Drug Profile
TG 1050
Alternative Names: TG-1050Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Transgene
- Developer Transgene; Transgene - Tasly Pharmaceutics Group (JV)
- Class Hepatitis B vaccines; Peptide vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Hepatitis-B(Treatment-experienced) in Canada (SC, Injection)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Hepatitis-B(Treatment-experienced) in France (SC, Injection)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Hepatitis-B(Treatment-experienced) in Germany (SC, Injection)